TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20087330

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg) enema treatment once daily for 14 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mesalazine (1 g) enema treatment once daily for 14 days
Number of subjects: 14
Study: 18237696

Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) ACL reconstruction
Number of subjects: 70

Group type: COMPARATOR
Intervention: Single-bundle (SB) ACL reconstruction
Number of subjects: 70
Study: 16601218

Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Knowledge of Performance (KP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 37
Study: 12745200

Group type: EXPERIMENTAL
Intervention: verapamil SR plus trandolapril
Number of subjects: 463

Group type: COMPARATOR
Intervention: atenolol plus chlorthalidone
Number of subjects: 463
Study: 10950038

Group type: EXPERIMENTAL
Intervention: Pancrelipase
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 9335444

Group type: EXPERIMENTAL
Intervention: Screened persons (faecal occult blood test)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Not screened (control group)
Number of subjects: 206
Study: 8192751

Group type: COMPARATOR
Intervention: Circulating immune complexes
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Higher levels of circulating immune complexes
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Moderately or poorly differentiated tumors
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: High ratio of immune complex-dissociated to native antibody titer
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Native antibody titers
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Immune complex levels
Number of subjects: 221
Study: 2421120

Group type: EXPERIMENTAL
Intervention: Non-cemented prostheses
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cemented prostheses
Number of subjects: 36
Study: 31345627

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (combined groups, every 2 weeks and every 3 weeks)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (combined groups)
Number of subjects: 834
Study: 29127483

Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) of dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 13
Study: 27855365

Group type: COMPARATOR
Intervention: RFA alone (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RFA plus CIK (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: RFA (in 8 patients with CEA > 50 ng/mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CIK cell therapy (in 8 patients with CEA > 50 ng/mL)
Number of subjects: 60
Study: 23727530

Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive and yoked training groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal working memory performance
Number of subjects: 0
Study: 22614972

Group type: EXPERIMENTAL
Intervention: Reduced-calorie weight loss diet
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity aerobic exercise
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combined reduced-calorie weight loss diet and moderate- to vigorous-intensity aerobic exercise
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control
Number of subjects: 439
Study: 20485161

Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 26000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26000
Study: 18949289

Group type: EXPERIMENTAL
Intervention: Propolis orabase gel (PRO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nystatin (NYS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole (FLU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deionized water (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orabase gel without active component (Control)
Number of subjects: 0
Study: 15695321

Group type: EXPERIMENTAL
Intervention: CCK-8 (1.8 pmol.kg(‐1).min(‐1))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GLP-1 (0.9 pmol.kg(‐1).min(‐1))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CCK-8 (1.8 pmol.kg(‐1).min(‐1)) and GLP-1 (0.9 pmol.kg(‐1).min(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 9
Study: 11838857

Group type: EXPERIMENTAL
Intervention: ASMP course (6 week course)
Number of subjects: 113

Group type: COMPARATOR
Intervention: ASMP manual (control)
Number of subjects: 113
Study: 10084271

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily (add-on therapy to timolol)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Pilocarpine 2% three times daily (add-on therapy to timolol)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily (switch from timolol)
Number of subjects: 148
Study: 8747987

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (HD-CY) or dose-escalated ifosfamide/mitoxantrone followed by filgrastim (R-metHuG-CSF, 300 micrograms/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sequential high-dose treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study: 1905614

Group type: EXPERIMENTAL
Intervention: Etidronate disodium (Didronel; 750 mg orally daily)
Number of subjects: 9
Study: 6367862

Group type: COMPARATOR
Intervention: CMF (cytoxan, methotrexate, and 5-fluorouracil)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: CMF plus tamoxifen (CMFT)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: CMFT plus BCG vaccinations
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: ER measurements in primary tumor
Number of subjects: 312
Study: 31046082

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort A)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort B)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort A and B)
Number of subjects: 376
Study: 30198412

Group type: EXPERIMENTAL
Intervention: Bedside condition
Number of subjects: 573

Group type: COMPARATOR
Intervention: Policy condition
Number of subjects: 573
Study: 27430301

Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up care in the community
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard hospital outpatient care
Number of subjects: 0
Study: 24256611

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22520738

Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy (STT)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Long-term psychotherapy (LPP)
Number of subjects: 326
Study: 20414536

Group type: EXPERIMENTAL
Intervention: SIRS-CPB
Number of subjects: 101
Study: 18640457

Group type: EXPERIMENTAL
Intervention: Dimebon (60 mg/day, 20 mg three times a day)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 16143731

Group type: EXPERIMENTAL
Intervention: IPSRT (Interpersonal and Social Rhythm Therapy)
Number of subjects: 175

Group type: COMPARATOR
Intervention: ICM (Intensive Clinical Management)
Number of subjects: 175
Study: 12133397

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg + MPA 2 mg + Ca-D 1 tablet daily (Group A)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg + MPA 2 mg + Ca-D 1 tablet daily (Group B)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Cal-D 1 tablet daily alone (Group C)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Vaginal bleeding rate in Group A
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Endometrium biopsies in Groups A and B
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Adverse events in Group A
Number of subjects: 236
Study: 10394089

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 5 mg (n = 6)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Naloxone 2.4 mg (n = 6)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (sterile water, n = 5)
Number of subjects: 17
Study: 8749725

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2202773

Group type: EXPERIMENTAL
Intervention: Erythromycin Base Filmtab (nonenteric-coated) at 1 g/d
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Erythromycin Base Filmtab (nonenteric-coated) at 2 g/d
Number of subjects: 368

Group type: COMPARATOR
Intervention: Eryc (enteric-coated) at 1 g/d
Number of subjects: 368

Group type: COMPARATOR
Intervention: Eryc (enteric-coated) at 2 g/d
Number of subjects: 368
Study: 45211

Group type: EXPERIMENTAL
Intervention: IV almitrine 0.5 mg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: IV doxapram 1 mg/kg
Number of subjects: 16
Study: 30146666

Group type: EXPERIMENTAL
Intervention: Reimagine (online symptom self-management curriculum)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 89
Study: 28693447

Group type: EXPERIMENTAL
Intervention: Psycho-education intervention (n = 170) at 24 and 34 weeks of pregnancy
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (n = 169)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Psycho-education intervention
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 339
Study: 26189067

Group type: EXPERIMENTAL
Intervention: Investigational group (oxaliplatin + fluorouracil)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Control group (fluorouracil only)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Investigational group (oxaliplatin + fluorouracil during chemoradiotherapy)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Control group (fluorouracil during chemoradiotherapy)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Investigational group (oxaliplatin + leucovorin + fluorouracil during adjuvant chemotherapy)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Control group (fluorouracil + leucovorin during adjuvant chemotherapy)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Investigational group (preoperative and postoperative treatment)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Control group (preoperative and postoperative treatment)
Number of subjects: 1236
Study: 24026523

Group type: EXPERIMENTAL
Intervention: EX/RP (exposure and ritual prevention)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 23241242

Group type: EXPERIMENTAL
Intervention: ADDITION-PRO cohort participants
Number of subjects: 2182
Study: 20840711

Group type: EXPERIMENTAL
Intervention: Current douching practices among women
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Influence of health care providers and family members
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Perception of vaginal douching
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Therapeutic value of vaginal douching
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Education on risks of vaginal douching
Number of subjects: 41
Study: 17249845

Group type: EXPERIMENTAL
Intervention: Bortezomib (PS-341)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactacystin
Number of subjects: 0
Study: 15308586

Group type: EXPERIMENTAL
Intervention: Tomato oleoresin extract (3 capsules daily for 2 weeks, each containing 4.88 mg lycopene, 0.48 mg phytoene, 0.44 mg phytofluene, and 1.181 mg alpha-tocopherol)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11160057

Group type: EXPERIMENTAL
Intervention: L‐NMMA (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: L‐arginine (375 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: L‐NMMA vs L‐arginine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: L‐NMMA and L‐arginine
Number of subjects: 24
Study: 9748428

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 1000 microgram administered twice daily at 08:00 h and 20:00 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 10
Study: 8046314

Group type: EXPERIMENTAL
Intervention: Pirprofen (400 mg t.i.d.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen (500 mg b.i.d.)
Number of subjects: 40
Study: 3149456

Group type: EXPERIMENTAL
Intervention: Orchiectomy plus nonsteroid antiandrogen (Anandron)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchiectomy plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total androgen blockade
Number of subjects: 0
Study: 29334983

Group type: EXPERIMENTAL
Intervention: Family Check‐Up 4 Health (FCU4Health) program
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 350
Study: 26676676

Group type: EXPERIMENTAL
Intervention: Early start of flap training (FT) on day 3
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard start of flap training (FT) on day 7
Number of subjects: 49
Study: 24905321

Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 2.5 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 5 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 10 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride (all doses)
Number of subjects: 42
Study: 23536652

Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy
Number of subjects: 12
Study: 20832550

Group type: EXPERIMENTAL
Intervention: Thromboelastography (TEG) monitoring
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard laboratory measures of blood coagulation monitoring
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TEG monitoring
Number of subjects: 28

Group type: COMPARATOR
Intervention: TEG monitoring and Standard laboratory measures
Number of subjects: 28
Study: 18607338

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0
Study: 15757062

Group type: EXPERIMENTAL
Intervention: Herbal product use
Number of subjects: 227

Group type: COMPARATOR
Intervention: Preoperative assessment
Number of subjects: 227
Study: 12668582

Group type: EXPERIMENTAL
Intervention: Oral linezolid (375, 500, or 625 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous linezolid (500 or 625 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10565448

Group type: EXPERIMENTAL
Intervention: Fortified human milk (group II)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Preterm formula (group III)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Human milk alone (group I)
Number of subjects: 3
Study: 8927676

Group type: EXPERIMENTAL
Intervention: Bipolar disorder with comorbid ADHD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bipolar disorder without ADHD
Number of subjects: 30
Study: 1671434

Group type: EXPERIMENTAL
Intervention: Carbamazepine or phenobarbitone treatment
Number of subjects: 302
Study: 6306348

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy (Cytoxan, CCNU, methotrexate + radiation to brain, chest, and abdomen)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Chemotherapy alone (Cytoxan, CCNU, methotrexate)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Partial response to therapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 145
Study: 31026780

Group type: EXPERIMENTAL
Intervention: Active TNS group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 24
Study: 29178317

Group type: EXPERIMENTAL
Intervention: Client‐driven, customized self‐management program with up to 3 in‐home visits from a registered nurse or registered dietitian, a monthly group wellness program, monthly provider team case conferences, and care coordination and system navigation.
Number of subjects: 159

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 159
Study: 26739392

Group type: EXPERIMENTAL
Intervention: High hs‐TnT level (≥14 ng/l) in diabetic group
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: hs‐TnT in multivariate model
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: hs‐CRP, B‐type natriuretic peptide, and sST2 in diabetic group
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: sST2 in nondiabetic group
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: hs‐CRP in nondiabetic group
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: hs‐TnT inclusion in model
Number of subjects: 1786
Study: 24413493

Group type: EXPERIMENTAL
Intervention: Intermediate Nugent score (4-6)
Number of subjects: 2920

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (Nugent score 7-10)
Number of subjects: 2920

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis excluding participants with TV at baseline
Number of subjects: 2920
Study: 22085757

Group type: EXPERIMENTAL
Intervention: TAU plus concreteness training (CNT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: TAU plus relaxation training (RT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 121
Study: 21290836

Group type: COMPARATOR
Intervention: Medication (antihistamine and anti-HP infection)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Acupoint catgut embedding therapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Medication combined with acupoint catgut embedding therapy
Number of subjects: 92
Study: 17890862

Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg b.i.d.
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg b.i.d.
Number of subjects: 386
Study: 15050376

Group type: EXPERIMENTAL
Intervention: Focused analgesia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Generalized relaxation
Number of subjects: 15
Study: 11549982

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate 42 mcg via metered dose inhaler twice daily
Number of subjects: 429

Group type: COMPARATOR
Intervention: Oral zafirlukast 20 mg twice daily
Number of subjects: 429
Study: 9613227

Group type: EXPERIMENTAL
Intervention: Spot light (S)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: General light (G)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mixed light (M)
Number of subjects: 16
Study: 7640145

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 100 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 200 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 50 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 2502417

Group type: EXPERIMENTAL
Intervention: 20 mg simvastatin
Number of subjects: 34

Group type: COMPARATOR
Intervention: 16 g cholestyramine
Number of subjects: 34
Study: 1107359

Group type: EXPERIMENTAL
Intervention: Intramuscular nefopam HCl 20 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intramuscular pethidine 50 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral nefopam HCl 60 mg t.i.d. for three days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral placebo t.i.d. for three days
Number of subjects: 100
Study: 29170121

Group type: EXPERIMENTAL
Intervention: Subjective feelings of personal relative deprivation (PRD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimentally-induced PRD
Number of subjects: 0
Study: 26796706

Group type: EXPERIMENTAL
Intervention: HP35 (35% hydrogen peroxide)
Number of subjects: 48

Group type: COMPARATOR
Intervention: HP6 (6% hydrogen peroxide with nitrogen-doped titanium oxide)
Number of subjects: 48
Study: 24503910

Group type: EXPERIMENTAL
Intervention: Individualized deliberate practice (DP) on a virtual reality simulator
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional residency training (Control)
Number of subjects: 16
Study: 24101183

Group type: EXPERIMENTAL
Intervention: Alpha neurofeedback training (20 sessions within 20 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-neurofeedback control group (no training sessions)
Number of subjects: 13
Study: 20575304

Group type: EXPERIMENTAL
Intervention: Sizhi‐Xifang treatment in the treatment group (24 cases) after incision healing
Number of subjects: 49

Group type: COMPARATOR
Intervention: Minimal invasive percutaneous plate treatment in the control group
Number of subjects: 49
Study: 19048106

Group type: EXPERIMENTAL
Intervention: Amnioreduction (drainage of 2000 ml fluid, range 700‐3500 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control procedures
Number of subjects: 40
Study: 15124952

Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 42
Study: 11818767

Group type: EXPERIMENTAL
Intervention: Clonidine (10 microg x kg(‐1) administered over 5 min + 5 microg x kg(‐1) x h(‐1) intravenous) given before mu-opioid receptor blockade
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clonidine (10 microg x kg(‐1) administered over 5 min + 5 microg x kg(‐1) x h(‐1) intravenous) given after mu-opioid receptor blockade
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mu-opioid receptor blockade (naloxone)
Number of subjects: 14
Study: 9561877

Group type: EXPERIMENTAL
Intervention: DDD pacing from ventricular apex
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DDD pacing from right ventricular outflow tract (RVOT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DDD pacing from proximal septum (His bundle area)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (apical pacing)
Number of subjects: 21